Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hunterase ICV approved in Japan for MPS II

Jan. 25, 2021

Galecto Biotech identifies new LGALS1 and/or LGALS3 inhibitors

Jan. 25, 2021

Oramed begins randomization in phase III study of oral insulin capsule ORMD-0801

Jan. 22, 2021

Lyndra initiates phase I study of its rosuvastatin extended-release capsule

Jan. 22, 2021

Cell therapy targeting BCL11A gene safely induces erythrocyte fetal hemoglobin

Jan. 22, 2021

U.S. IND application cleared for UX-701 gene therapy for Wilson disease

Jan. 22, 2021

FDA approves Darzalex Faspro for newly diagnosed light-chain amyloidosis

Jan. 18, 2021

Glutamine aids and abets senescent cell survival

Jan. 15, 2021

Bimagrumab improves traits in patients with type 2 diabetes and obesity

Jan. 15, 2021

Fochon Pharmaceuticals synthesizes new URAT1 inhibitors

Jan. 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...